Cybin to participate at the pathways to access summit and the interdisciplinary conference on psychedelic research 2024

Toronto--(business wire)--cybin inc. (nyse american:cybn) (cboe ca:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that amir inamdar, mbbs, dnb (psych), mfpm, cybin's chief medical officer, and ellen james, ph.d., cybin's director, clinical development, will participate at the interdisciplinary conference on psychedelic.
CYBN Ratings Summary
CYBN Quant Ranking